Demographic and other baseline characteristics for SAF
| 30 mg (n=290) | Total (n=513) | |
| Sex, female, no. (%) | 211 (72.8) | 390 (76.0) |
| Age, years | 55.8±11.9 | 55.8±11.6 |
| Age <65 years, no. (%) | 209 (72.1) | 371 (72.3) |
| Weight, kg | 59.22±13.28 | 58.95±12.92 |
| Disease duration, years | 7.2±7.1 | 7.6±7.5 |
| Concomitant MTX, no. (%) | 196 (67.6) | 373 (72.7) |
| Concomitant csDMARDs except for MTX, no. (%) | 51 (17.6) | 72 (14.0) |
| Corticosteroid use, no. (%) | 133 (45.9) | 228 (44.4) |
Demographic and other baseline characteristics at the start of the trials for SAF.
csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; MTX, methotrexate; SAF, safety analysis set.